Oncology News

CHICAGO — Potentially targetable oncogenic rearrangements are more prevalent among patients with KRAS wild-type pancreatic cancer than those with KRAS-mutated disease, according to study results presented at ASCO Annual Meeting.

Ibex Medical Analytics has obtained CE mark for Galen Gastric, an artificial intelligence-powered diagnostic solution for the detection of various types of gastric cancers, the company announced in a press release.

The AGA has released a series of evidence-based position statements that support a nationwide colorectal cancer screening approach and aim to eliminate current barriers in the screening process.

In a Healio video exclusive, Chris Evans, president of the Colon Cancer Coalition and Healio’s 2021 Patient Voice Disruptive Innovator, shares updates on the organization’s recent accomplishments and future plans.

In a Healio video exclusive, Chris Evans, president of the Colon Cancer Coalition and Healio’s 2021 Patient Voice Disruptive Innovator, shares updates on the organization’s recent accomplishments and future plans.

We have long known that our diets affect our health, but many questions remain about diet’s impact on conditions like cancer and its potential value in treating a wide variety of health conditions.

Calling the research “beyond impressive” and “absolutely remarkable,” HCPs took to Twitter to heap praise on study results presented at the ASCO Annual Meeting describing treatment with dostarlimab in a subset of rectal cancer patients.

SAN DIEGO — In a Healio video exclusive, study authors Howard P. Monsour, MD, and Carrie Milliard, discuss how genetic risk assessment and testing may help inform patient care and improve health outcomes.

The potential for ctDNA-guided management to reduce adjuvant chemotherapy by half without compromising recurrence-free survival sparked interest on social media after a presentation at the ASCO Annual Meeting.

CHICAGO — Dostarlimab, an anti-PD-1 monoclonal antibody, demonstrated a 100% clinical complete response rate among a small cohort of patients with mismatch repair-deficient locally advanced rectal cancer, phase 2 study results showed.